Shine On You Crazy ...
Health Care: Drugs
NovaBay Pharmaceuticals Inc. (NBY: AMEX)
$1.34 -0.03 | -2.19%
05/21/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 6.95M | 11.02M | 9.75M | 15.68M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 6.95M | 11.02M | 9.75M | 15.68M |
| Selling, General, and Administrative Expenses | 5.98M | 5.43M | 5.65M | 5.61M |
| Research & Development | 9.28M | 9.91M | 8.62M | 7.34M |
| Operating Income before D & A (EBITDA) | -8.31M | -4.32M | -4.52M | 2.74M |
| Depreciation & Amortization | 341.00K | 425.00K | 427.00K | 373.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 1.28M | -762.00K | 258.00K | -36.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -7.37M | -5.51M | -4.68M | 2.33M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -7.37M | -5.51M | -4.68M | 2.33M |
| Income Taxes | 2.00K | 2.00K | 50.00K | 7.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -7.03M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -7.03M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -7.03M | -5.08M | -4.31M | 2.70M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-7.03M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -7.03M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.24 | -0.20 | -0.18 | 0.12 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.24 | -0.20 | -0.18 | 0.12 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.24 | -0.20 | -0.18 | 0.12 |
| Basic Normalized Net Income/Share | -0.24 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.24 | -0.20 | -0.18 | 0.12 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.24 | -0.20 | -0.18 | 0.12 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.24 | -0.20 | -0.18 | 0.12 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.24 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with NBY
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Contributor10 Biotech Stocks Expected ...
- UserRAPTOR SPRTD-0705091614
- Usermartynorm Portfolio 1
Latest NBY Headlines from TheStreet
- NovaBay Pharmaceuticals Reports First Quarter Financial Results And Clinical And Business Update 05.02.13 | 08:05 am
- NovaBay Global Ophthalmology Study Enrolls First Patients In Brazil 04.08.13 | 07:04 am
- NovaBay CEO Interviewed On RedChip Money Report On Fox Business News 03.18.13 | 06:03 am
- NovaBay Pharmaceuticals Reports Fourth Quarter Financial Results And 2013 Clinical And Business Update 03.14.13 | 06:03 am
- NovaBay Pharmaceuticals To Present At The 25th Annual ROTH Conference 03.12.13 | 07:03 am
- NovaBay Names Keith Bley As Senior Vice President Of Product Development 03.11.13 | 07:03 am
- NovaBay Receives Unique Globally Recognized International Nonproprietary Name Auriclosene For NVC-422 02.20.13 | 07:02 am
- NovaBay Partner Galderma Expands Phase 2b Trial Enrollment To South Africa 02.05.13 | 07:02 am
- NovaBay Pharmaceuticals To Present At The 15th Annual BIO CEO & Investor Conference 01.31.13 | 07:01 am
- NovaBay Pharmaceuticals Announces Smartphone Investor App 01.15.13 | 08:01 am
Press Releases for NBY
Partner Headlines for NBY
- NovaBay: Working On An Effective Treatment For Viral Conjunctivitis - Seeking Alpha 04.13.13 | 08:04 am
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Diverse Pipeline And Multiple Catalysts Point To Buying Opportunity In NovaBay Pharmaceuticals - Seeking Alpha 09.06.12 | 09:09 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Novabay Announces Neutrophase Available in Spray Pump - Benzinga 08.27.12 | 09:08 am
- NovaBay Pharmaceuticals: A Potential Bargain With Catalysts Pending - Seeking Alpha 06.13.12 | 09:06 am
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- NovaBay Pharmaceuticals: Key Deal Marks A Year Of Swift Progression - Seeking Alpha 01.10.12 | 08:01 am
